Recent Updates
Recently added Catalysts
ELAN Negative Sentiment Score: 25/100

ELANCO ANIMAL HEALTH INCORPORATED (NYSE: ELAN) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Elanco Animal Health Incorporated Investors of Upcoming Deadline

Key Takeaway: Bernstein Liebhard LLP has issued a reminder to investors of Elanco Animal Health Incorporated (NYSE: ELAN) regarding an upcoming deadline in a securities fraud class action lawsuit. The lawsuit, which involves allegations of misrepresentation about the FDA approval timeline for products Zenrelia and Credelio Quattro, covers shares purchased between November 7, 2023, and June 26, 2024. Those interested in serving as lead plaintiff must file by December 6, 2024. Investors may contact Bernstein Liebhard LLP for more details on their legal rights and the implications of the lawsuit.

Market Sentiment Analysis

CONCERNS & RISKS

  • A securities fraud class action lawsuit has been filed against Elanco.
  • The lawsuit alleges misrepresentations regarding FDA approval and launch timelines for key products.
  • Investors are reminded of a deadline to file as lead plaintiff, which may indicate ongoing legal troubles.

Full Press Release Details

NEW YORK, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP:
Do you, or did you, own shares of Elanco Animal Health Incorporated (NYSE: ELAN)?
Did you purchase your shares between November 7, 2023 and June 26, 2024, inclusive?
Did you lose money in your investment in Elanco Animal Health Incorporated?
Do you want to discuss your rights?
Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Elanco Animal Health Incorporated (“Elanco” or the “Company”) (NYSE: ELAN) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company.
If you purchased or acquired Elanco securities, and/or would like to discuss your legal rights and options please visit Elanco Animal Health Incorporated Shareholder Class Action Lawsuit or contact Investor Relations Manager Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com.
A lawsuit was filed in the United States District Court for the District of Maryland on behalf of investors who purchased or acquired the securities of Elanco between November 7, 2023 and June 26, 2024, inclusive (the “Class Period”), alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its senior officers.
According to the lawsuit, Defendants made misrepresentations concerning the timeline for U.S. Food and Drug Administration approval and commercial launch for two of the Company’s products, Zenrelia and Credelio Quattro.
If you wish to serve as lead plaintiff for the Class, you must file papers by December 6, 2024. A lead plaintiff is a representative party acting on other class members’ behalf in directing the litigation. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member.
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of class actions, the Firm has been named to The National Law Journal’s “Plaintiffs’ Hot List” thirteen times and listed in The Legal 500 for sixteen consecutive years.
ATTORNEY ADVERTISING. © 2024 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Contact Information:
Investor Relations Manager
Bernstein Liebhard LLP

Tags

elanco animal health
class action lawsuit

Frequently Asked Questions

What is the deadline for the Elanco lawsuit?

The deadline to file as lead plaintiff is December 6, 2024.

Who can participate in the Elanco class action lawsuit?

Investors who bought Elanco shares between November 7, 2023, and June 26, 2024, can participate.

What are the allegations against Elanco?

Elanco is accused of misrepresenting FDA approval and product launch timelines.

Are there any fees for participating in the lawsuit?

Shareholders pay no fees or expenses; all representation is contingency-based.

Who should I contact for more information about the lawsuit?

Contact Investor Relations Manager Peter Allocco at (212) 951-2030.

Last updated: Nov 19, 2024